The FDA has approved Roche’s Wilserdly (giredestrant), a next-generation oral selective estrogen receptor degrader, in combination with everolimus for adults with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer, according to a Nov. 16 news release.
Here are six things to know:
- The approval covers locally advanced or metastatic disease, as detected by an FDA-authorized test, that recurred during or after adjuvant endocrine therapy or progressed on at least one endocrine-based regimen in the metastatic setting.
- The approval is based on the phase 3 evERA trial, published in the New England Journal of Medicine, which compared Wilserdly plus everolimus with standard endocrine therapy plus everolimus in patients whose disease progressed after a CDK4/6 inhibitor.
- In patients with ESR1 mutations, the combination reduced the risk of disease progression or death by 62% (hazard ratio, 0.38; 95% confidence interval, 0.27 to 0.54), according to Roche. The finding applies to the ESR1-mutated population, the subgroup for which the FDA approved the drug.
- Roche called Wilserdly the first all-oral next-generation SERD combination to significantly outperform a standard endocrine combination in this setting in a head-to-head phase 3 trial.
- It joins other oral options for ESR1-mutated disease. The FDA approved Eli Lilly’s imlunestrant, an oral estrogen receptor antagonist, in September 2025 for ESR1-mutated advanced or metastatic disease that progressed after at least one prior endocrine therapy. Imlunestrant showed a median progression-free survival of 5.5 months, compared with 3.8 months for standard endocrine therapy, among 256 patients with ESR1 mutations.
- The FDA is also reviewing Wilserdly as an adjuvant treatment for ER-positive, HER2-negative stage I to III breast cancer at intermediate to high risk of recurrence, with a decision expected Nov. 30. If approved, Roche said, it would be the first SERD approved for both adjuvant and advanced disease and the first new adjuvant endocrine therapy in more than 20 years.
At the Becker's Perioperative Summit, taking place September 14–15 in Chicago, perioperative leaders and healthcare executives will focus on improving operating room efficiency, enhancing patient safety, optimizing staffing and driving innovation across surgical services. Apply for complimentary registration now.
